Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Slides:

Advertisements

Similar presentations

Volume 42, Issue 5, Pages (May 2005)

Advertisements

Triangles and dotted lines are for mean values. , P <

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Psychosocial Correlates of Symptoms in Functional Dyspepsia

Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Clinical Epidemiology and Global Health

Health-Related Quality-of-Life Measures: Evidence from Tunisian Population Using the SF-12 Health Survey Moheddine Younsi, PhD Value in Health Regional.

Volume 61, Issue 5, Pages (November 2014)

The Impact of Pain Management on Quality of Life

Postoperative pain after abdominal hysterectomy: a randomized, double-blind, controlled trial comparing continuous infusion vs patient-controlled intraperitoneal.

Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement J.M. Quintana, Ph.D., A. Escobar, M.D., A. Bilbao,

Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement A. Escobar, M.D., J.M. Quintana, Ph.D., A. Bilbao,

Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity Nina K. Grewal,

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Changes in evaluation indicators from baseline to 12 weeks per visit.

Comparison of recovery after mitral valve repair and replacement

Mu Qin et al. JACEP 2017;j.jacep

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

Clinical Epidemiology and Global Health

Seth D. Crockett, Quinn K. Lippmann, Evan S. Dellon, Nicholas J

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.

Percentage of patients reporting improvements ≥MCID and NNTs to achieve an MCID in (A) PtGA, (B) pain, (C) HAQ-DI, (D) FACIT-F and (E) SF-36 domains and.

Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.

The Journal of Allergy and Clinical Immunology: In Practice

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.

Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.

Association between PGIC and change (Δ) in (A) Pain (VAS), (B) PGA, (C) FIQ, (D) HAQ, (E) Body Map, (F) MPQ). Association between PGIC and change (Δ) in.

SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations.

Mean individual and summative SF-36 V2 scores before and 3 months after ablation. Mean individual and summative SF-36 V2 scores before and 3 months after.

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Clinical response in patients with early and established RA at month 24. *p

Least squares mean (LSM) changes from baseline in (A) Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total score and (B) Ankylosing.

Patient-reported quality of life after abdominal aortic aneurysm surgery: A prospective comparison of endovascular and open repair Badr Aljabri, MD,

Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.

Percentage of patients with RA achieving DAS28(CRP)<2

Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form.

Spydergram of mean SF-36 domain scores at baseline and weeks 12 (A) and 24 (B) for sarilumab 150 mg and 200 mg+csDMARDs compared with placebo+csDMARDs.

Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment Ralf W. Sprengers, MD, Martin Teraa,

Percentage of patients in each treatment group whose biomarker values returned to normal reference ranges at week 24. Percentage of patients in each treatment.

Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in.

Spider plot of the unstandardised SF-36v2 subscales, comparing our HCM population with the mean for the general population (aged 45–54 years). Spider plot.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

J. J. Smith, FRCS, A. M. Garratt, PhD, M. Guest, FRCS, R. M

Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.

Satisfaction with control of RA

Explanatory power of the LPA solution for clinical and functional outcomes compared with the conventional threshold-based discordance definition. Explanatory.

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

LPA groups display vastly different outcomes.

Systematic review and network meta-analyses study selection flow chart

Patient disposition. *Patients who switched multiple times were not included in this analysis; **for patients switching treatment regimens, discontinuations.

Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.

Presentation transcript:

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. (A) Patient global assessment (PtGA), Pain visual analogue scale, FACIT-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), SF-36 physical and mental component scores (PCS and MCS), morning stiffness visual analogue scale and Rheumatoid Arthritis Impact of Disease (RAID). (B) SF-36 individual domains. *p<0.05 for the response rate relative to placebo. †p<0.0001 for the response rate relative to placebo. ‡p<0.001 for the response rate relative to placebo. BP, Bodily Pain; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; GH, General Health perceptions; MH, Mental Health; NNT, number needed to treat; PF, Physical Functioning; RE, Role Emotional; RP, Role Physical; SF, Social Functioning; VT, Vitality. Vibeke Strand et al. RMD Open 2017;3:e000416 Copyright © BMJ Publishing Group & EULAR. All rights reserved.